NYSE:ABTAbbott Laboratories Stock Price, Forecast & News

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABT stock has increased by 1.7% and is now trading at $79.45. View which stocks have been mosted impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Abbott Laboratories.

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, April 16th 2020. View our earnings forecast for Abbott Laboratories.

Abbott Laboratories will be holding an earnings conference call on Thursday, April 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Abbott Laboratories (NYSE:ABT) released its earnings results on Wednesday, January, 22nd. The healthcare product maker reported $0.95 EPS for the quarter, hitting the consensus estimate of $0.95. The healthcare product maker had revenue of $8.31 billion for the quarter, compared to analyst estimates of $8.26 billion. Abbott Laboratories had a net margin of 11.56% and a return on equity of 18.39%. The company's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the company earned $0.81 EPS. View Abbott Laboratories' earnings history.

Abbott Laboratories declared a quarterly dividend on Friday, February 21st. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.36 per share on Friday, May 15th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date is Tuesday, April 14th. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.08. View Abbott Laboratories' dividend history.

Abbott Laboratories updated its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.60.

18 brokerages have issued twelve-month target prices for Abbott Laboratories' shares. Their forecasts range from $81.00 to $105.00. On average, they anticipate Abbott Laboratories' share price to reach $94.43 in the next twelve months. This suggests a possible upside of 18.9% from the stock's current price. View analysts' price targets for Abbott Laboratories.

News coverage about ABT stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abbott Laboratories earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the healthcare product maker a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutAbbott Laboratories.

Abbott Laboratories saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 23,053,500 shares, an increase of 21.5% from the February 27th total of 18,970,000 shares. Based on an average daily trading volume, of 5,550,000 shares, the short-interest ratio is presently 4.2 days. Approximately 1.3% of the company's stock are sold short. View Abbott Laboratories' Current Options Chain.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD), Masimo (MASI) and Hologic (HOLX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Walt Disney (DIS), NVIDIA (NVDA), Home Depot (HD), Pfizer (PFE), Verizon Communications (VZ) and Intel (INTC).

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Park National Corp OH (0.03%), First Financial Bank Trust Division (0.01%), Woodstock Corp (0.01%), Cullinan Associates Inc. (0.01%), Neville Rodie & Shaw Inc. (0.00%) and Bath Savings Trust Co (0.00%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Philip P Boudreau, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View institutional ownership trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Birch Capital Management LLC, IMS Capital Management, Neville Rodie & Shaw Inc., Orrstown Financial Services Inc., and Woodstock Corp. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Philip P Boudreau, Randel William Woodgrift, Sally E Blount, and Stephen R Fussell. View insider buying and selling activity for Abbott Laboratories.

ABT stock was bought by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., Fulton Bank N.A., First Financial Bank Trust Division, Bath Savings Trust Co, Thomasville National Bank, Summit Financial Group Inc., and Nexus Investment Management Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift. View insider buying and selling activity for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $79.45.

Abbott Laboratories has a market capitalization of $140.10 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe. View additional information about Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.